Abstracts tagged "Disease Activity"

Abstract Number: 0827 • ACR Convergence 2020
Comparative Clinical Efficacy of Sarilumab versus Upadacitinib over 12 Weeks: Matching-Adjusted Indirect Comparison Analysis
Thomas Huizinga¹, Ernest Choy², Amy Praestgaard³, Hubert van Hoogstraten⁴, Patrick R LaFontaine³, Patricia Guyot⁵, Daniel Aletaha⁶, Ulf Müller-Ladner⁷, Yoshiya Tanaka⁸, Jeffrey R Curtis⁹ and Roy Fleischmann¹⁰, ¹Leiden University Medical Center, Leiden, Netherlands, ²CREATE Centre, Cardiff University, Cardiff, Wales, United Kingdom, ³Sanofi, Cambridge, MA, ⁴Sanofi, Bridgewater, NJ, ⁵Sanofi, Chilly-Mazarin, France, ⁶Division of Rheumatology, Department of Medicine III, Medical University of Vienna,, Vienna, Austria, ⁷Department of Rheumatology and Clinical Immunology, Justus-Liebig University, Campus Kerckhoff, Bad Nauheim, Germany, ⁸The First Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ¹⁰Southwestern Medical Center, Metroplex Clinical Research Center, Dallas, TX
Background/Purpose: Sarilumab, an IL-6 receptor inhibitor, and upadacitinib, a Janus kinase (JAK) 1 inhibitor, are both approved for the treatment of patients with moderately to…
Abstract Number: 0940 • ACR Convergence 2020
In Patients with Inflammatory Arthritides Central Pain Sensitization Is Strictly Associated with Functional Disability
Giovanni Adami¹, Angelo Fassio¹, Elisabetta Gerratana², Alessandro Giollo¹, Camilla Benini¹, Luca Idolazzi¹, Elisabetta Vantaggiato¹, Davide Gatti¹ and Maurizio Rossini¹, ¹Rheumatology Unit, University of Verona, Verona, Italy, ²Rheumatology Unit, University of Messina, Messina, Italy
Background/Purpose: Long-term nociceptive pain, as in inflammatory arthritides, can cause Central Sensitization (CS) to pain. CS Inventory (CSI) is a validated screening instrument for clinicians to…
Abstract Number: 1228 • ACR Convergence 2020
Baricitinib 2-mg Provides Greater Improvements in Patient-Reported Outcomes Across All Disease Activity Levels Compared to Placebo: Post-hoc Analyses of RA-BEACON and RA-BUILD Trials
Clifton Bingham III¹, Bochao Jia², Jianmin Wu², Amanda Quebe², Carol Kannowski², Susan Otawa², Yun-Fei Chen², Kirstin Griffing², Dongyi He³ and Dalton Sholter⁴, ¹Johns Hopkins University, Baltimore, MD, ²Eli Lilly and Company, Indianapolis, IN, ³Shanghai Guanghua Hospital, Shanghai, Shanghai, China (People's Republic), ⁴University of Alberta, Edmonton, AB, Canada
Background/Purpose: Baricitinib (BARI) improved patient-reported outcomes (PROs) in patients with insufficient response or intolerance to ≥1 tumor necrosis factor inhibitors (TNFi) or other biological disease-modifying…
Abstract Number: 1357 • ACR Convergence 2020
Comparative Efficacy of Janus Kinase Inhibitors and TNF Inhibitors in Ankylosing Spondylitis: A Network Meta-Analysis
Adela Castro¹, Jesus Diaz², Guillermo Quiceno³ and John Cush⁴, ¹UT Southwestern, Dallas, TX, ²Universidad de los Andes, Dallas, TX, ³UT Southwestern Medical Center, Dallas, TX, ⁴University of Texas Southwestern Medical School, Dallas, TX
Background/Purpose: Active ankylosing spondylitis (AS) has been associated with poor quality of life and work disability in up to 50% of patients (1). There is…
Abstract Number: 1715 • ACR Convergence 2020
Longitudinal Patterns of Remission in Real-World Early Rheumatoid Arthritis Patients: Results from the Canadian Early Arthritis Cohort (CATCH)
Orit Schieir¹, Glen Hazlewood², Susan Bartlett³, Marie-France Valois³, Louis Bessette⁴, Gilles Boire⁵, Carol Hitchon⁶, Edward Keystone⁷, Janet Pope⁸, Carter Thorne⁹, Diane Tin⁹, Vivian Bykerk¹⁰ and Canadian Early Arthritis Cohort (CATCH) Investigators¹¹, ¹Canadian Early Arthritis Cohort Study, Montreal, Canada, ²University of Calgary, Calgary, AB, Canada, ³McGill University, Montreal, Canada, ⁴Laval University, Quebec, Canada, ⁵Universite de Sherbrooke, Sherbrooke, Canada, ⁶University of Manitoba, Winnipeg, MB, Canada, ⁷The Rebecca MacDonald Centre for Arthritis, Mt. Sinai Hospital, Toronto, Canada, ⁸Department of Medicine, University of Western Ontario, St. Joseph's Health Centre, London, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY, ¹¹Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Early diagnosis and rapid initiation of DMARDs following a treat-to-target approach have made remission a realizable goal for many persons living with RA. Despite…
Abstract Number: 1810 • ACR Convergence 2020
Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine
Anne Margrethe Troldborg¹, Annette Hansen², Kristian Stengaard-Pedersen² and Steffen Thiel², ¹Aarhus University Hospital, Arhus, Denmark, ²Aarhus University, Aarhus, Denmark
Background/Purpose: Mortality in patients with systemic lupus erythematosus (SLE) is significantly higher than in the general population. Treatment of SLE patients has improved, however, a…
Abstract Number: 1984 • ACR Convergence 2020
Causal Pathways to Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the ReACCh-Out Cohort
Kiem Oen¹, Jiahao Tian², Thomas Loughin², Roberta Berard³, Mercedes Chan⁴, Ciaran Duffy⁵, Brian Feldman⁶, Adam Huber⁷, Deborah Levy⁸, Dax G. Rumsey⁹, Natalie Shiff¹⁰, Shirley Tse¹¹, Lori Tucker⁴, Karen Watanabe-Duffy⁵ and Jaime Guzman¹², ¹University of Manitoba, Toronto, ON, Canada, ²Simon Fraser University, Burnaby, BC, Canada, ³London Health Sciences Centre, London, ON, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Florida, Gainesville, FL, ¹¹SickKids, Toronto, ON, Canada, ¹²University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The relative roles of disease activity and disability as determinants of health-related quality of life (HRQoL) in children with JIA have been controversial; sometimes…
Abstract Number: 0169 • ACR Convergence 2020
Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis
Juliette Yedimenko¹, Jessica Walsh², Alexis Ogdie³, Yuxuan Jin¹, Soumya Reddy⁴, Jose Scher⁵ and M. Elaine Husni¹, ¹Cleveland Clinic, Cleveland, OH, ²University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, New York City
Background/Purpose: For psoriatic arthritis (PsA), several different composite instruments are available to define low disease activity (LDA) and remission (REM) targets for treatment. Patient-reported outcomes…
Abstract Number: 0313 • ACR Convergence 2020
Swollen Joints but Not Tender Joints Are Associated with Ultrasound Power Doppler Synovitis in Very Early DMARD Naive Psoriatic Arthritis
Sayam Dubash¹, Oras Alabas¹, Xabier Michelena¹, Leticia Garcia-Montoya¹, Gabriele De Marco², Mira Merashli³, Richard Wakefield¹, Philip Helliwell⁴, Ai Lyn Tan¹, Dennis McGonagle¹, Paul Emery⁵ and Helena Marzo-Ortega¹, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Treviglio, Italy, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Beirut, Lebanon, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Clinical tender and swollen joint counts are used for biologic drug eligibility and clinical trial inclusion criteria. Ultrasonography (US) adds to clinical examination as…
Abstract Number: 0616 • ACR Convergence 2020
Correlation Between Disease Activity and Perceived Economic Barriers to Care in a Population of African American Women with Systemic Lupus Erythematosus
Ashley White¹, Trevor Faith¹, Aissatou Ba¹, Viswanathan Ramakrishnan², Hetlena Johnson³, Jillian Rose⁴, Clara Dismuke-Greer⁵, Jim Oates⁶, Leonard Egede⁷ and Edith Williams¹, ¹Medical University of South Carolina, Charleston, SC, ²medical university of south carolina, south carolina, ³LupusCSC, Columbia, SC, ⁴Hospital for Special Surgery, New York, ⁵Palo Alto VA, Palo Alto, CA, ⁶Medical University of South Carolina, Charleston, SC, Charleston, SC, ⁷Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex, multifactorial disease with heterogeneous presentation. Disease activity – the number and severity of symptoms – can be…
Abstract Number: 0828 • ACR Convergence 2020
Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study
Stanley B Cohen¹, Yi-Hsing Chen², Naonobu Sugiyama³, Jose L Rivas⁴, Annette Diehl⁵, Tatjana Lukic⁶, Jerome Paulissen⁷, Haiyun Fan⁵, Tomohiro Hirose³ and Edward C Keystone⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer SLU, Madrid, Spain, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Syneos Health, Morrisville, NC, ⁸Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: ORAL Shift (NCT02831855) was a 48-week Phase 3b/4 study, which demonstrated sustained efficacy/safety of tofacitinib modified release 11 mg once daily (QD) following MTX…
Abstract Number: 0983 • ACR Convergence 2020
Outcomes Following Antimalarial Withdrawal in Patients with Quiescent Systemic Lupus Erythematosus
Danae Papachristos¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarial medications (AMs) are central to the management of SLE, affording numerous clinical benefits including the reduction of disease flare. However, little is known…
Abstract Number: 1229 • ACR Convergence 2020
Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis
Eulalia Rodriguez-Martín¹, Israel Nieto-Gañán¹, Borja Hernández-Breijo², Cristina Sobrino³, Carlota García-Hoz¹, Javier Bachiller-Corral⁴, Ana Martínez-Feito⁵, Victoria Navarro-Compán⁶, Paloma Lapuente-Suanzes¹, Gema Bonilla⁷, Dora Pascual-Salcedo⁸, Garbiñe Roy¹, Teresa Jurado², Pilar Nozal², Mónica Vázquez⁴, Alejandro Balsa⁷, Luisa M Villar¹ and Chamaida Plasencia⁷, ¹Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain, ²Hospital Universitario La Paz-Idipaz, Madrid, Spain, ³Hospital Ramón y Cajal-IRYCIS, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁵Hospital Unversitario La Paz- idipaz, Madrid, Spain, ⁶Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁷Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ⁸Hospital Universitario La Paz- Idipaz, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFis) are widely used for the treatment of rheumatoid arthritis (RA), although the response rates to this therapy in patients with RA…
Abstract Number: 1362 • ACR Convergence 2020
BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study
Nathan den Broeder¹, Michelle Mulder¹, Mark Wenink¹, Alfons den Broeder¹, Lise Verhoef², Frank van den Hoogen¹ and C.A.J Michielsens¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) have proven to be safe and effective in the treatment of axial spondyloarthritis (axSpA). However, they carry some disadvantages,…
Abstract Number: 1723 • ACR Convergence 2020
RA Flare Prediction via Machine Learning and Algorithm Based on SSDM Big Data
Yan Zhao¹, Rong Mu², Xiaomei Li³, Hongsheng Sun⁴, Cundong Mi⁵, Guosheng Wang³, Shengqian Xu⁶, Minghua Xu⁷, Haiying Chen⁸, Qingchun Huang⁹, Ling Lei¹⁰, HaiLi Shen¹¹, Hui Xiao¹², Yuhua Jia¹³, Bing Wu¹³, Xin Chen¹², Shengsong Jia¹² and Fei Xiao¹³, ¹Peking Union Medical College hospital, Beijing, Beijing, China (People's Republic), ²People's Hospital, Beijing University Medical School, Beijing, Beijing, China (People's Republic), ³the First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China (People's Republic), ⁴Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China (People's Republic), ⁵The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), ⁶the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (People's Republic), ⁷Affiliated Hospital of Hebei University, Baoding, Hebei, China (People's Republic), ⁸The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic), ⁹Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China (People's Republic), ¹⁰The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), ¹¹Second Hospital of Lanzhou University, Lanzhou, Gansu, China (People's Republic), ¹²Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹³Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic)
Background/Purpose: Flare, relapse from status of treat-to-target (T2T, DAS28< =3.2), is hard predicted. We try to make it predictable by applying machine learning to a…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].